Listed

Agios Pharmaceuticals, Inc.

AGIONasdaqCIK 1439222HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$44.7mRevenue, Q2 FY2026, three months to 2026-06-30$44.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Jul 30, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$44.7mRevenue, Q2 FY2026, three months to 2026-06-30$44.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure+259.3% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−247.1%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$110.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Revenue: $44.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure+773.0 pts on a year earlier
  • Net margin−225.1%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$100.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Revenue: $44.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure+674.3 pts on a year earlier
  • Diluted EPS−$1.69Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.69 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure+12.4% on a year earlier
  • Free cash flow−$58.5mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$57.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-30, accession 0001439222-26-000118. Derived: 6-month figure less the 3-month figure.Capital expenditure: $1.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-30, accession 0001439222-26-000118. Derived: 6-month figure less the 3-month figure.Report this figure+25.0% on a year earlier

Last eight quarters

Full statements
Revenue$44.7mOperating margin −247.1%
Diluted EPS−$1.69, Q2 FY2026
Free cash flow−$58.5m, Q2 FY2026
Agios Pharmaceuticals, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m9.0Revenue, Q3 FY2024, three months to 2024-09-30$9.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure10.7Revenue, Q4 FY2024, three months to 2024-12-31$10.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure8.7Revenue, Q1 FY2025, three months to 2025-03-31$8.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure12.5Revenue, Q2 FY2025, three months to 2025-06-30$12.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure12.9Revenue, Q3 FY2025, three months to 2025-09-30$12.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure20.0Revenue, Q4 FY2025, three months to 2025-12-31$20.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure20.7Revenue, Q1 FY2026, three months to 2026-03-31$20.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure44.7Revenue, Q2 FY2026, three months to 2026-06-30$44.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(1146.9%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$102.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Revenue: $9.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure(1165.3%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$125.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Revenue: $10.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure(1222.0%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$106.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Revenue: $8.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure(1020.1%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$127.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Revenue: $12.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure(907.4%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$116.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Revenue: $12.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure(608.9%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$121.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Revenue: $20.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure(530.3%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$110.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Revenue: $20.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure(247.1%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$110.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Revenue: $44.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure
Net margin%10574.7%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $947.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Revenue: $9.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure(899.6%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$96.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Revenue: $10.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure(1023.3%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$89.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Revenue: $8.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure(899.4%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$112.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Revenue: $12.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure(803.1%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$103.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Revenue: $12.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figure(541.1%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$108.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Revenue: $20.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure(477.7%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$99.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Revenue: $20.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure(225.1%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$100.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Revenue: $44.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure
Diluted EPS$ per share16.22Diluted EPS, Q3 FY2024, three months to 2024-09-30$16.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figurenot reported (Diluted EPS not reported)(1.55)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$1.55 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure(1.93)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$1.93 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure(1.78)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$1.78 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-30, accession 0001439222-25-000116.Report this figurenot reported (Diluted EPS not reported)(1.69)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$1.69 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure(1.69)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.69 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0001439222-26-000118.Report this figure
Free cash flow$m(84.6)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$84.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-30, accession 0001439222-25-000116. Derived: 9-month figure less the 6-month figure.Capital expenditure: $419.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-30, accession 0001439222-25-000116. Derived: 9-month figure less the 6-month figure.Report this figure(134)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$133.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Capital expenditure: $967.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure(112)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$111.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Capital expenditure: $766.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure(78.0)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$77.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-30, accession 0001439222-26-000118. Derived: 6-month figure less the 3-month figure.Capital expenditure: $875.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-30, accession 0001439222-26-000118. Derived: 6-month figure less the 3-month figure.Report this figure(89.7)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$88.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-30, accession 0001439222-25-000116. Derived: 9-month figure less the 6-month figure.Capital expenditure: $1.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-30, accession 0001439222-25-000116. Derived: 9-month figure less the 6-month figure.Report this figure(97.3)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$96.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Capital expenditure: $1.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-12, accession 0001439222-26-000025. Derived: 12-month figure less the 9-month figure.Report this figure(120)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$118.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Capital expenditure: $769.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-29, accession 0001439222-26-000073.Report this figure(58.5)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$57.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-30, accession 0001439222-26-000118. Derived: 6-month figure less the 3-month figure.Capital expenditure: $1.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-30, accession 0001439222-26-000118. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$54.0mOperating margin −873.9%
Diluted EPS−$7.12, FY2025
Free cash flow−$377.3m, FY2025
Agios Pharmaceuticals, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m0.0Revenue, FY2021, twelve months to 2021-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-15, accession 0001439222-24-000035.Report this figure14.2Revenue, FY2022, twelve months to 2022-12-31$14.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-13, accession 0001439222-25-000009.Report this figure26.8Revenue, FY2023, twelve months to 2023-12-31$26.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001439222-26-000025.Report this figure36.5Revenue, FY2024, twelve months to 2024-12-31$36.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001439222-26-000025.Report this figure54.0Revenue, FY2025, twelve months to 2025-12-31$54.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001439222-26-000025.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%not reported (Revenue of zero not reported)(2732.1%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$389.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-13, accession 0001439222-25-000009.Revenue: $14.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-13, accession 0001439222-25-000009.Report this figure(1459.5%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$391.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-12, accession 0001439222-26-000025.Revenue: $26.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001439222-26-000025.Report this figure(1166.5%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$425.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-12, accession 0001439222-26-000025.Revenue: $36.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001439222-26-000025.Report this figure(873.9%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$472.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-12, accession 0001439222-26-000025.Revenue: $54.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001439222-26-000025.Report this figure
Net margin%not reported (Revenue of zero not reported)(1627.8%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$231.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-13, accession 0001439222-25-000009.Revenue: $14.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-13, accession 0001439222-25-000009.Report this figure(1312.6%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$352.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-12, accession 0001439222-26-000025.Revenue: $26.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001439222-26-000025.Report this figure1845.9%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $673.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-12, accession 0001439222-26-000025.Revenue: $36.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001439222-26-000025.Report this figure(764.0%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$412.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-12, accession 0001439222-26-000025.Revenue: $54.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-12, accession 0001439222-26-000025.Report this figure
Diluted EPS$ per share26.55Diluted EPS, FY2021, twelve months to 2021-12-31$26.55 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-15, accession 0001439222-24-000035.Report this figure(4.23)Diluted EPS, FY2022, twelve months to 2022-12-31−$4.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-13, accession 0001439222-25-000009.Report this figure(6.33)Diluted EPS, FY2023, twelve months to 2023-12-31−$6.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-12, accession 0001439222-26-000025.Report this figure11.64Diluted EPS, FY2024, twelve months to 2024-12-31$11.64 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-12, accession 0001439222-26-000025.Report this figure(7.12)Diluted EPS, FY2025, twelve months to 2025-12-31−$7.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-12, accession 0001439222-26-000025.Report this figure
Free cash flow$m(413)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$407.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-15, accession 0001439222-24-000035.Capital expenditure: $5.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-15, accession 0001439222-24-000035.Report this figure(314)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$309.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-13, accession 0001439222-25-000009.Capital expenditure: $4.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-13, accession 0001439222-25-000009.Report this figure(297)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$296.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-12, accession 0001439222-26-000025.Capital expenditure: $999.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-12, accession 0001439222-26-000025.Report this figure(392)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$389.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-12, accession 0001439222-26-000025.Capital expenditure: $1.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-12, accession 0001439222-26-000025.Report this figure(377)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$373.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-12, accession 0001439222-26-000025.Capital expenditure: $4.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-12, accession 0001439222-26-000025.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

By month, by reported value, last 24 monthsPurchases $0Sales $74.6k
Agios Pharmaceuticals, Inc., open-market insider transactions
DateInsiderTransactionSharesReported priceValueFiling
2026-10-22Gheuens SarahChief Medical Officer, Officer Sale500$37.52$18.8kForm 4
2026-10-21Gheuens SarahChief Medical Officer, Officer Sale1,489$37.53$55.9kForm 4

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Agios Pharmaceuticals, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$239.6m6,455,997Added+701,040
FARALLON CAPITAL MANAGEMENT, L.L.C.2026-06-30$219.6m5,917,400Added+233,400
STATE STREET CORP2026-06-30$131.1m3,533,633Added+168,754
Lynx1 Capital Management LP2026-06-30$126.5m3,408,937Added+797,369
D. E. Shaw & Co., Inc.2026-06-30$115.3m3,107,005Added+425,836
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$107.6m2,898,197Added+287,162
ARMISTICE CAPITAL, LLC2026-06-30$104.3m2,810,000CallReduced−390,000
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$99.5m2,681,845Added+49,529
ARMISTICE CAPITAL, LLC2026-06-30$89.1m2,400,000Reduced−316,000
Erste Asset Management GmbH2026-06-30$82.0m2,154,900Reduced−550,000

Recent filings

All 1,292 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Agios Pharmaceuticals, Inc., recent filings
FiledFormWhat it isAccession number
2026-07-3009:56 ET10-QQuarterly reportPeriod 2026-06-300001439222-26-000118
2026-07-3006:32 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001439222-26-000115
2026-06-1816:13 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001193125-26-275879
2026-04-2909:22 ET10-QQuarterly reportPeriod 2026-03-310001439222-26-000073
2026-04-2906:32 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001439222-26-000071
2026-04-2416:01 ETDEF 14AProxy statementPeriod 2026-06-180001193125-26-177086
2026-02-1209:33 ET10-KAnnual reportPeriod 2025-12-310001439222-26-000025
2026-02-1206:32 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001439222-26-000023
2026-01-1207:11 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001439222-26-000018
2025-10-3009:57 ET10-QQuarterly reportPeriod 2025-09-300001439222-25-000116

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 12, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1439222
Tickers
AGIO
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer
Former names
AGIOS PHARMACEUTICALS INC (to 2019-07-16)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:12 ET. Listed shows no prices and gives no investment advice.